Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of NBP607QIV vs Agrippal in Healthy Adults
NCT03826719Phase 2Completed
- Sponsor
- SK Chemicals
- Start
- Feb 2014
- Primary completion
- Mar 2014
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 2, randomised, double-blind trial of NBP607-V in influenza (2 arms), sponsored by SK Chemicals. Primary endpoints: Incidence rate of solicited local adverse events at 7 days, Incidence rate of solicited systemic adverse events at 7 days and 1 more. Started Feb 2014; status: completed.
02
Drugs
NBP607-V
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03826719.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03826719.